Диссертация (Прогностическая модель для оценки риска развития миелотоксических осложнений химиотерапевтического лечения), страница 28

39. № 44(3). – C. 1338.93. Hitron, A. Incidence and risk factors of clinically significant chemotherapyinduced thrombocytopenia in patients with solid tumors. / A. Hitron, D. Steinke,S. Sutphin, et al. // J Oncol Pharm Pract. – 2011. – № 17(4). – C. 312-9.94. Hoskins, L.M. UGT1A1*28 genotype and irinotecan-induced neutropenia: dosematters. / L.M. Hoskins, R.M. Goldberg, P. Qu, J.G. Ibrahim, H.L.

McLeod // JNatl Cancer Inst – 2007. – № 99(17). – C. 1290-5.95. Hosmer, D.W. Applied Logistic Regression / D.W. Hosmer, S.A. Lemeshow,R.X. Sturdivant. Wiley, 2013. – 528.96. Hu, Z.Y. Dose-dependent association between UGT1A1*28 genotype andirinotecan-induced neutropenia: low doses also increase risk / Z.Y. Hu, Q. Yu, Q.Pei, C.

Guo // Clin Cancer Res. – 2010. – № 16(15). – C. 3832-3842.97. Hughes, W.T. Guidelines for the use of antimicrobial agents in neutropenicpatients with unexplained fever: a statement by The Infectious Disease Society ofAmerica / W.T. Hughes, D. Armstrong, G.P. Bodey, et al. // J Infect Dis. – 1990.– № 161. – C. 381-400.98. Leipzig, U. Prognostische Faktoren für Hämatotixizität. Toxic risk calculator /Institut für Medizinische Informatik, Statistik und Epidemiologie. UniversitätLeipzig.

URL: https://home.uni-leipzig.de/arndowski/httm.php (дата обращения:24.07.2019).99. Khanbhai, M. The problem of anaemia in patients with colorectal cancer / M.Khanbhai, M. Shah, G. Cantanhede, S. Ilyas, T. Richards // ISRN Hematol –2014. – Т. 2014. № 95. – C. 13-20.100. Kleinbaum, D.G. Logistic Regression A Self‐Learning Text / D.G. Kleinbaum,M. Klein. – New York: Springer, 2010. – 709.101. Ludwig, H. The European Cancer Anaemia Survey (ECAS): a large,multinational, prospective survey defining the prevalence, incidence, andtreatment of anaemia in cancer patients.

/ H. Ludwig, S.v. Belle, P. Barrett-Lee, etal. // Eur J Cancer – 2004. – № 40 (15). – C. 2293-306.102. Ludwig, H. Prevalence and management of anemia in patients (pts) withhematologic malignancies (HMs) and solid tumors (STs): results from theEuropean Cancer Anaemia Survey (ECAS) [abstract]. / H. Ludwig, G. Birgegard,P. Barrett-Lee, et al. // Blood – 2002. – № 100.

– C. 234a-5a.166103. Lugtenburg, P. Impact of age group on febrile neutropenia risk assessment andmanagement in patients with diffuse large B-cell lymphoma treated with RCHOP regimens. / P. Lugtenburg, A.S. Silvestre, F.G. Rossi, et al. // ClinLymphoma Myeloma Leuk. – 2012. – № 12(5). – C. 297-305.104. Lyman, G.H. Assessing patients’ risk of febrile neutropenia is there a correlationbetween physician-assessed risk and model-predicted risk? / G.H. Lyman, D.C.Dale, J.C. Legg, E.

Abella, P.K. Morrow, S. Whittaker, J. Crawford // CancerMed – 2015. – Т. 4(8). – C. 1153-60.105. Lyman, G.H. Prospective validation of a risk model for first cycle neutropeniccomplications in patients receiving cancer chemotherapy / G.H. Lyman, N.M.Kuderer, J. Crawford, et al. // J Clin. Oncol – 2006. – Т.

24, ASCO AnnualMeeting Proceedings Part I. № 18S. – C. 8561.106. Lyman, G.H. Predicting individual risk of neutropenic complications in patientsreceiving cancer chemotherapy. / G.H. Lyman, N.M. Kuderer, J. Crawford, D.A.Wolff, E. Culakova, M.S. Poniewierski, D.C.

Dale // Cancer – 2011. – Т.1;117(9). – C. 1917-27.107. Lyman, G.H. Risk models for predicting chemotherapy-induced neutropenia. /G.H. Lyman, C.H. Lyman, N.M. Kuderer, O. Agboola // The Oncologist – 2005.– № 10. – C. 427-37.108. Macdougall, I.C. Incidence of erythropoietin antibody-mediated pure red cellaplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS) / I.C.Macdougall, N.

Casadevall, F. Locatelli, C. Combe, et al. // Nephrol DialTransplant – 2015. – № 30. – C. 451-60.109. Maione, P. Pretreatment quality of life and functional status assessmentsignificantly predict survival of elderly patients with advanced non-small-celllung cancer receiving chemotherapy: a prognostic analysis of the multicenterItalian lung cancer in the elderly study / P. Maione, F.

Perrone, C. Gallo, e. al. // JClin Oncol. – 2005. – № 23. – C. 6865-72.110. Marec-Berard, P. Risk model predictive of severe anemia requiring RBCtransfusion after chemotherapy in pediatric solid tumor patients/ / P. MarecBerard, J.Y. Blay, M. Schell, al. // J Clin Oncol.

– 2003. – № 21(22). – C. 4235-8.111. Miller, A. Reporting Results of Cancer Treatment / A. Miller, B. Hoogstraten, M.Staquet, A. Winkler // Cancer – 1981. – Т. 47. – C. 207-214.112. Mosteller, R.D. Simplified calculation of body-surface area. / R.D. Mosteller // NEngl J Med – 1987. – № 317(17). – C. 1098.113. MASCC Guidelines / Multinational Association for Supportive Care inCancer™, 2016. URL: https://mascc.memberclicks.net/guidelines (датаобращения: 04.05.2019).114. NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 /National Cancer Institute, 2006.

URL:167115.116.117.118.119.120.121.122.123.124.125.http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (дата обращения: 18.05.2019).NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 /National Cancer Institute, 2010.

URL:https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_200905-29_QuickReference_8.5x11.pdf (дата обращения: 18.05.2019).NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 /National Cancer Institute, 2017. URL:https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения: 24.09.2019).NCI Common Toxicity Criteria / National Cancer Institute, 1999.

URL:http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcmanual_v4_10-4-99.pdf (дата обращения: 18.05.2019).NCCN Guidelines version 1.2019 Management of Neutropenia / NationalComprehensive Cancer Network, 2019. URL:https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf (датаобращения: 24.05.2019).Oken, M.M.

Toxicity and response criteria of the Eastern Cooperative OncologyGroup / M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T.McFadden, P.P. Carbone // Am J Clin Oncol – 1982. – № 5(6). – C. 649-55.Paugh, S.W. Cancer pharmacogenomics / S.W. Paugh, G. Stocco, J.R. McCorkle,B. Diouf, K.R. Crews, W.E.

Evans // Clin Pharmacol Ther – 2011. – № 90(6). –C. 461-466.Pfeil, A.M. Efficacy, effectiveness and safety of long-acting granulocyte colonystimulating factors for prophylaxis of chemotherapy-induced neutropenia inpatients with cancer: a systematic review / A.M. Pfeil, k, K. Allcott, R. Pettengell,G.v. Minckwitz, M. Schwenkglenks, Z. Szabo // Support Care Cancer – 2015.

–№ 23. – C. 3131-40.Pivot, X. An analysis of potential factors allowing an individual prediction ofcisplatin-induced anaemia / X. Pivot, E. Guardiola, M. Etienne, e. al. // Eur JCancer – 2000. – № 36. – C. 852–57.Rajda, J. Semantic Interoperability of Health Risk Assessments. / J. Rajda, D.J.Vreeman, H.G. Wei // American Medical Informatics Association SymposiumProc. – 2011. – – C. 1134–1143.Ray-Coquard, I.

Risk model for severe anemia requiring red blood celltransfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1Study Group. / I. Ray-Coquard, A.L. Cesne, M.T. Rubio, J Mermet et al. // J ClinOncol. – 1999. – № 17. – C.

2840-6.Logical Observation Identifiers Names and Codes (LOINC) / I. RegenstriefInstitute, 2019. URL: http://www.loinc.org (дата обращения: 23.09.2019).168126. Salvarini, C. The role of interleukine-1, erythropoietin and red cell boundimmunoglobulins in the anemia of rheumatoid arthritis. / C. Salvarini, B. Casali,D.S.

D, e. al // Clin Exp Rheumatol – 2000. – № 9. – C. 2414-6.127. Shibuya, M. Adverse drug reaction criteria of the Japan Society for CancerTherapy / M. Shibuya // Gan To Kagaku Ryoho – 1997. – № 24(14). – C. 203641.128. Simon, A.M. Fatigue in cancer patients / A.M. Simon, R. Zittoun // Curr OpinOncol – 1999.

– № 11. – C. 244-49.129. Sparano, J.A. Weekly paclitaxel in the adjuvant treatment of breast cancer. / J.A.Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, T. Saphner, A.C. Wolff,G.W. Sledge, W.C. Wood, N. Davidson // N Engl J Med – 2008. – № 358. – C.1663-71.130. Sparano, J.A. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating theRole of Taxane and Schedule in Operable Breast Cancer. / J.A. Sparano, F. Zhao,S. Martino, J.A.

Ligibel, E.A. Perez, T. Saphner, A.C.W.G.W. Sledge, W.C.Wood, N.E. Davidson // N Engl J Med – 2015. – № 33. – C. 2353-60.131. Spivak, J.L. Anemia management in oncology and hematology / J.L. Spivak, P.Gascón, H. Ludwig // Oncologist – 2009. – № 1. – C. 43-56.132. Stone, P. Fatigue in patients with cancer / P. Stone, M.

Richards, J. Hardy // Eur JCancer – 1998. – № 34. – C. 1670–76.133. Tampellini, M. The role of hemoglobin level in predicting the response to firstline chemotherapy in advanced colorectal cancer (ACC) patients / M. Tampellini,A. Saini, L. Alabiso, e. al. // Br J Cancer – 2006. – № 95.

– C. 13-20.134. MedDRA / The International Council on Harmonisation of TechnicalRequirements for Registration of Pharmaceuticals for Human Use (ICH), 2016.URL: http://www.ich.org/products/meddra.html (дата обращения: 14.05.2019).135. Vaupel, P. Hypoxia and aggressive tumor phenotype: implications for therapyand prognosis / P. Vaupel // Oncologist – 2008. – № 3.

– C. 21-26.136. Wood, P.A. Cisplatin-associated anemia: An erythropoietin deficiency syndrome/ P.A. Wood, W.J. Hrushesky // J Clin Invest – 1995. – № 95. – C. 1650-59.137. WHO Handbook for Reporting Results of Cancer Treatment. / World HealthOrganization // WHO Offset publication – 1979. – № 48.138. Ziepert, M. Prognostic factorsfor hematotoxicity of chemotherapy inaggressivenon-Hodgkin’s lymphoma / M.

Ziepert, R. Schmits, L. Trümper, at al.// Ann Oncol. – 2008. – Т. v. 19(4). – C. p.752-62..